Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2025)

Vivos Therapeutics' Retained Earnings history spans 7 years, with the latest figure at -$125.4 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$125.4 million for Q4 2025, down 20.32% from a year ago — trailing twelve months through Dec 2025 was -$125.4 million (down 20.32% YoY), and the annual figure for FY2025 was -$125.4 million, down 20.32%.
  • Retained Earnings for Q4 2025 was -$125.4 million at Vivos Therapeutics, down from -$118.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$38.7 million in Q1 2021 to a low of -$125.4 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$87.7 million (2023), against an average of -$84.2 million.
  • The sharpest move saw Retained Earnings tumbled 58.84% in 2022, then fell 11.66% in 2025.
  • Year by year, Retained Earnings stood at -$55.6 million in 2021, then crashed by 42.87% to -$79.5 million in 2022, then decreased by 17.09% to -$93.1 million in 2023, then dropped by 11.97% to -$104.2 million in 2024, then dropped by 20.32% to -$125.4 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$125.4 million, -$118.5 million, and -$113.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.